A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B.

Henry Lik Yuen ChanD MessingerGeorgios Papatheodoridis Markus CornbergQ XieT PiratvisuthH RenP T KennedyA ThompsonA CaputoG Bakalos Vedran Pavlovic Pietro Lampertico

Published in: Alimentary pharmacology & therapeutics (2018)

A pre-treatment scoring system using readily available baseline characteristics identifies HBeAg-positive Asian patients likely to experience sustained HBeAg seroconversion after treatment with peginterferon alfa-2a.

Keyphrases

hepatitis b virus
end stage renal disease
ejection fraction
replacement therapy
newly diagnosed
chronic kidney disease
peritoneal dialysis
patient reported outcomes